Standard Chemotherapy for Myelomatosis: An Area of Great Controversy

Aitchison, 1990, Vincristine, Adriamycin and high dose steroids in myeloma complicated by renal failure, Br J Cancer, 61, 765, 10.1038/bjc.1990.171 Alexanian, 1990, Renal failure in multiple myeloma. Pathogenesis and prognostic implication, Arch Intern Med, 150, 1693, 10.1001/archinte.1990.00040031693017 Alexanian, 1990, VAD-based regimens as primary treatment for multiple myeloma, Am J Hematol, 33, 86, 10.1002/ajh.2830330203 Alexanian, 1984, Chemotherapy for multiple myeloma, Cancer, 53, 583, 10.1002/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1 Alexanian, 1978, Unmaintained remission in multiple myeloma, Blood, 51, 1005, 10.1182/blood.V51.6.1005.1005 Alexanian, 1969, Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens, JAMA, 208, 1680, 10.1001/jama.1969.03160090040009 Alexanian, 1981, Chemoimmunotherapy for multiple myeloma, Cancer, 47, 1923, 10.1002/1097-0142(19810415)47:8<1923::AID-CNCR2820470802>3.0.CO;2-Z Alexanian, 1977, Combination therapy for multiple myeloma, Cancer, 49, 2765, 10.1002/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X Back, 1990, Single-dose intravenous melphalan in advanced multiple myeloma, Acta Haematol, 83, 183, 10.1159/000205210 Barlogie, 1989, Review article: Plasma cell myeloma— new biological insights and advances in therapy, Blood, 73, 865, 10.1182/blood.V73.4.865.865 Barlogie, 1991, Bone marrow transplantation in multiple myeloma, Bone Marrow Transpl, 7, 71 Barlogie, 1989, High serum levels of lactic dehydrogenase identify a high grade lymphoma like myeloma, Ann Intern Med, 110, 521, 10.7326/0003-4819-110-7-521 Barlogie, 1984, Effective treatment of advanced multiple myeloma refractory to alkylating agents, N Engl J Med, 310, 1353, 10.1056/NEJM198405243102104 Belch, 1988, A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients, Br J Cancer, 57, 94, 10.1038/bjc.1988.17 Bergsagel, 1979, The chemotherapy of plasma cell myeloma and the incidence of acute leukemia, N Engl J Med, 301, 743, 10.1056/NEJM197910043011402 Bergsagel, 1988, Chemotherapy of myeloma: Drug combinations versus single agents: An overview, and comments on acute leukemia in myeloma, Hematol Oncol, 6, 159, 10.1002/hon.2900060216 Bergsagel, 1972, Plasma cell myeloma: Response of melphalan resistant patients to high dose intermittent cyclophosphamide, Can Med Assoc J, 107, 851 Bergsagel, 1989, Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?, Eur J Cancer Clin Oncol, 25, 159, 10.1016/0277-5379(89)90001-1 Bergsagel, 1975, Mouse myeloma. A model for studies of cell kinetics, Arch Intern Med, 135, 109, 10.1001/archinte.1975.00330010111014 Bladé, 1990, A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma, Blut, 60, 319, 10.1007/BF01737844 Boccadoro, 1991, Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma, Eur J Haematol, 47, 305, 10.1111/j.1600-0609.1991.tb01576.x Boccadoro, 1987, Lack of correlation between plasma cell thymidine labelling index and serum beta-2 microglobulin in monoclonal gammopathies, Acta Haematol, 78, 239, 10.1159/000205885 Boccadoro, 1983, Kinetics of circulating B lymphocytes in human myeloma, Blood, 61, 812, 10.1182/blood.V61.4.812.812 Boccadoro, 1989, Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis, J Clin Oncol, 7, 119, 10.1200/JCO.1989.7.1.119 Boccadoro, 1991, Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients, J Clin Oncol, 9, 444, 10.1200/JCO.1991.9.3.444 Boccadoro, 1987, Multiple myeloma: Biological and clinical significance of bone marrow plasma cell labelling index, Haematologica, 72, 171 Boccadoro, 1987, Cell kinetics of multiple myeloma, Hematol Pathol, 13, 137 Bosanquet, 1982, Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma, Eur J Cancer Clin Oncol, 18, 355, 10.1016/0277-5379(82)90006-2 Case, 1977, Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol, Am J Med, 63, 897, 10.1016/0002-9343(77)90543-5 Cavagnaro, 1980, Comparison of two combination chemotherapy regimens for multiple myeloma: Methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone, Cancer Treat Rep, 64, 73 1973, Guidelines for protocol studies, Cancer Chemother Rep, 4, 145 Cohen, 1984, Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma, Blood, 63, 639, 10.1182/blood.V63.3.639.639 Cuckle, 1980, Report on the second myelomatosis trial after five years of follow-up, Br J Cancer, 42, 813, 10.1038/bjc.1980.328 Cuzick, 1990, Long-term prognostic value of serum β2 microglobulin in myelomatosis, Br J Haematol, 75, 506, 10.1111/j.1365-2141.1990.tb07790.x Cuzick, 1980, Treatment comparisons in the third MRC myelomatosis trial, Br J Cancer, 42, 823, 10.1038/bjc.1980.329 Drewinko, 1981, The growth fraction of human myeloma cells, Blood, 57, 333, 10.1182/blood.V57.2.333.333 Durie, 1988, Chemotherapy of myeloma. SWOG studies, Hermatol Oncol, 6, 141, 10.1002/hon.2900060214 Durie, 1980, Reappraisal of plateau phase in myeloma, Lancet, 1, 65, 10.1016/S0140-6736(80)92941-4 Durie, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell with presenting clinical features, response to treatment and survival, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U Durie, 1980, Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma, Blood, 55, 364, 10.1182/blood.V55.3.364.364 Durie, 1990, Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group Study, Blood, 75, 823, 10.1182/blood.V75.4.823.823 Ehrsson, 1989, Oral melphalan pharmacokinetics—relation to dose in patients with multiple myeloma, Med Oncol Tumor Pharmacother, 6, 151, 10.1007/BF02985238 Fernberg, 1990, Oral dosage of melphalan and response to treatment in multiple myeloma, Eur J Cancer, 26, 393, 10.1016/0277-5379(90)90240-T Forgeson, 1988, Infused vincristine and Adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients, Br J Cancer, 58, 469, 10.1038/bjc.1988.243 Froom, 1990, Multiple myeloma in the geriatric patient, Cancer, 66, 965, 10.1002/1097-0142(19900901)66:5<965::AID-CNCR2820660526>3.0.CO;2-M Gianni, 1990, Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells, Bone Marrow Transpl, 6, 143 Goldie, 1982, Rationale for the use of alternating noncross-resistant chemotherapy, Cancer Treat Rep, 66, 439 Gore, 1989, Intensive treatment of multiple myeloma and criteria for complete remission, Lancet, 2, 879, 10.1016/S0140-6736(89)91548-1 Hansen, 1985, Phase III study of intermittent 5-drug regimen (VBMCP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis, Scand J Haematol, 35, 518, 10.1111/j.1600-0609.1985.tb02822.x Harley, 1979, Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB, Blood, 54, 13, 10.1182/blood.V54.1.13.13 Hjorth, 1990, Initial treatment in multiple myeloma: No advantage of multidrag chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden, Br J Haematol, 74, 185, 10.1111/j.1365-2141.1990.tb02564.x Jagannath, 1990, Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors, Blood, 76, 1860, 10.1182/blood.V76.9.1860.1860 Johnson, 1990, Treatment of renal failure associated with multiple myeloma, Arch Intern Med, 150, 863, 10.1001/archinte.1990.00390160111022 Karjalainen, 1989, Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland, Br Med J, 29, 1069, 10.1136/bmj.299.6707.1069 Kildahl-Anderson, 1988, Multiple myeloma in central and northern Norway 1981-1982: A follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy, Eur J Haematol, 41, 47, 10.1111/j.1600-0609.1988.tb00867.x Kyle, 1987, Is there a correct time to begin treatment of multiple myeloma?, Haematologica, 72, 107 Kyle, 1990, Newer approaches to the therapy of multiple myeloma, Blood, 76, 1678, 10.1182/blood.V76.9.1678.1678 Latreille, 1982, Ploidy and proliferative characteristics in monoclonal gammopathies, Blood, 59, 43, 10.1182/blood.V59.1.43.43 Lee, 1974, Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, and BCNU, Cancer, 33, 533, 10.1002/1097-0142(197402)33:2<533::AID-CNCR2820330231>3.0.CO;2-Z MacLennan, 1985, Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council working party on leukemia in adults, Br J Cancer, 52, 153, 10.1038/bjc.1985.171 MacLennan, 1988, Results of the MRC myelomatosis trials for patients entered since 1980, Hematol Oncol, 6, 145, 10.1002/hon.2900060215 Mandelli, 1990, Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. Results of an Italian randomized study, N Engl J Med, 322, 1430, 10.1056/NEJM199005173222005 McLaughlin, 1982, Myeloma protein kinetics following chemotherapy, Blood, 60, 851, 10.1182/blood.V60.4.851.851 1984, Analysis and management of renal failure in fourth MRC myelomatosis trial, Br Med J, 288, 1411, 10.1136/bmj.288.6428.1411 Omedé, 1990, Multiple myeloma: Increased circulating lymphocytes carrying plasma cell associated antigens as an indicator of poor survival, Blood, 76, 1375, 10.1182/blood.V76.7.1375.1375 Osgood, 1960, The survival time of patients with plasmocytic myeloma, Cancer Chemother Rep, 9, 1 Osterborg, 1990, Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden, Acta Oncol, 29, 727, 10.3109/02841869009092991 Osterborg, 1989, Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III—a randomized study from MGCS, Eur J Haematol, 43, 54, 10.1111/j.1600-0609.1989.tb01252.x Osterborg, 1989, Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients, Eur J Cancer Clin Oncol, 25, 899, 10.1016/0277-5379(89)90138-7 Paccaniella, 1983, Treatment of multiple myeloma with M-2 protocol and without maintenance chemotherapy, Eur J Cancer Clin Oncol, 19, 1345, 10.1016/0277-5379(93)90002-M Palmer, 1988, Dose intensity analysis of melphalan and prednisone in multiple myeloma, J Natl Cancer Inst, 80, 414, 10.1093/jnci/80.6.414 Palmer, 1989, Reassessment of the relationship between Mprotein decrement and survival in multiple myeloma, Br J Cancer, 59, 110, 10.1038/bjc.1989.22 Palva, 1987, Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone: A randomized multicenter trial, Eur J Haematol, 38, 50 Palva, 1989, Treatment of multiple myeloma in old patients, Eur J Haematol, 43, 328 Pavlovsky, 1988, An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus threeand five-drug combinations: A GATLA study, J Clin Oncol, 6, 769, 10.1200/JCO.1988.6.5.769 Peest, 1988, Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VMCP, Eur J Cancer Clin Oncol, 24, 1061, 10.1016/0277-5379(88)90160-5 Petrucci, 1989, Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment, Eur J Haematol, 42, 233, 10.1111/j.1600-0609.1989.tb00104.x Pileri, 1976, Early recruitment in the human myeloma cell population after cytostatic treatment, Haematologica, 61, 184 Pileri, 1982, Human myeloma: Kinetics of the remission phase, Acta Haematol, 68, 237, 10.1159/000206986 Pileri, 1990, Complete remission in multiple myeloma. Letter to the Editor, Lancet, 335, 52, 10.1016/0140-6736(90)90181-4 Pileri, 1990, GM-CSF peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma, Haematologica, 75, 79 Riccardi, 1991, Changing clinical presentation of multiple myeloma, Haematologica Riccardi, 1986, Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma, Eur J Cancer Clin Oncl, 22, 787, 10.1016/0277-5379(86)90364-0 Salmon, 1983, Alternating combination chemotherapy improves survival in multiple myeloma: A Southwest Oncology Group Study, J Clin Oncol, 1, 453, 10.1200/JCO.1983.1.8.453 Samson, 1989, Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma, Lancet, 2, 882, 10.1016/S0140-6736(89)91549-3 Solomon, 1991, Nephrotoxic potential of Bence Jones proteins, N Engl J Med, 324, 1845, 10.1056/NEJM199106273242603 Sviland, 1987, Short course intermediate dose intravenous melphalan therapy in myeloma—relation to early emergence of drug resistance (phase II study), Acta Haematol, 78, 233, 10.1159/000205884 Tarella C, Boccadoro M, Frieri R, et al: High-dose sequential (HDS) pilot chemoradiotherapy for poor prognosis multiple myeloma. 2. Therapeutic efficacy and perspectives. In Abstract Book of III International Workshop on Multiple Myeloma, Torino, 1991, p 144 Tribalto, 1985, Treatment of multiple myeloma: A randomized study of three different regimens, Leuk Res, 9, 1043, 10.1016/0145-2126(85)90075-X van Hoeven, 1990, Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy, Cancer, 66, 1472, 10.1002/1097-0142(19901001)66:7<1472::AID-CNCR2820660706>3.0.CO;2-P